VitaSpring Biomedical Co., Ltd. reported no revenue for the three months ended April 30, 2025, similar to the same period in 2024. The company incurred a net loss of $80,541 for the quarter, an improvement from the $216,831 net loss in the prior year's quarter, primarily due to reduced operating expenses. Operating expenses decreased to $69,147 from $216,831 in the prior year, driven by lower professional fees, lease expenses, stock-based compensation, and payroll. The company's working capital deficiency increased by 1.94% to $4,107,358 as of April 30, 2025, from $4,029,306 as of January 31, 2025. As of April 30, 2025, the company had $0 in cash and total current assets of $295, against total current liabilities of $4,107,653. A material weakness in internal control over financial reporting was identified due to insufficient segregation of duties and lack of accounting personnel with appropriate U.S. GAAP and SEC reporting expertise. The company continues to rely on related-party financing and equity issuances, with substantial doubt existing about its ability to continue as a going concern within one year.